Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Hennigsdorf, Germany Clinical Trials

A listing of Hennigsdorf, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (33) clinical trials

Enbrel-Sulfasalazin-Early-Axial Spondyloarthritis (AS)

Randomized controlled study with two treatment arms (Phase II), 1 year open extension Efficacy - To assess efficacy of etanercept vs. sulfasalazine when added to NSAIDs in patients with moderate to severe active early axial spondyloarthritis duration of ongoing axial symptoms of less than 5 years. Primary outcome is change ...

Phase

4.92 miles

Learn More »

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

The primary objective of this study is to evaluate the testicular safety of filgotinib in adult males with moderately to severely active ulcerative colitis.

Phase

8.34 miles

Learn More »

A Single Inhalation Dose Study to Assess Efficacy Pharmacokinetics (PK) Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.

This randomized, double-blind, placebo and active-controlled crossover study will be conducted at 5 sites in Germany and the United Kingdom (UK). Approximately 180 patients will be screened in order to randomize 72 patients into the study. Based on previous studies estimate, it is anticipated that 54 patients will be evaluable ...

Phase

8.34 miles

Learn More »

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the clinical efficacy and safety of combination therapy with guselkumab and golimumab in participants with moderately to severely active ulcerative colitis (UC).

Phase

8.34 miles

Learn More »

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

GSK2586881, a purified intravenous (IV) formulation of soluble recombinant human Angiotensin Converting Enzyme (rhACE2) is being investigated as a treatment for PAH. This GlaxoSmithKline (GSK) study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK2586881 in subjects with PAH. This open-label, dose-escalation study will comprise of 4 ...

Phase

8.34 miles

Learn More »

Dose-finding Study to Assess the Efficacy Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection

This is a blinded, randomized, dose- and regimen finding trial where active TIP doses or placebo is given in addition to the local standard care.

Phase

8.46 miles

Learn More »

Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis

Phase 2 randomized, double-blind, placebo-controlled, parallel-group, multicenter, multi-national study to assess the efficacy, safety and tolerability, and pharmacokinetics (PK) of INS1007 administered once daily for 24 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFBE).

Phase

8.46 miles

Learn More »

A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA)

The total study duration per patient will be 166 weeks that will consist of a 4- week screening, a 12-week core treatment phase, a 144-week extension phase, and a 6-week post-treatment follow-up.

Phase

8.89 miles

Learn More »

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

Four hypotheses are tested in hierarchical order. To avoid inflation of type 1 error (false rejection of a null hypothesis), further confirmatory testing has to be stopped as soon as a null hypothesis could not be rejected. All four hypotheses are tested at significance level 0.05. Null hypotheses 1, 2, ...

Phase

8.89 miles

Learn More »

A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

This is a study to evaluate whether macitentan is an effective and safe treatment for patients with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease. The primary objective is to evaluate whether macitentan 10 mg reduces N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as compared to placebo in these ...

Phase

8.89 miles

Learn More »